Last reviewed: June 21, 2026
Last updated: June 21, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide is a GLP-1 receptor agonist that slows stomach emptying and signals fullness to the brain, leading to sustained appetite suppression. Clinical trials show an average weight loss of 15–22% of baseline body weight over 68 weeks, though monthly progress follows a pattern influenced by genetics and individual metabolism. Understanding realistic expectations helps patients stay committed to therapy.
Typical Monthly Weight Loss Range with Semaglutide
Most patients experience noticeable weight loss within the first four weeks of semaglutide therapy, though the timeline varies. During initial months on standard doses, typical weight loss ranges from 4–8 pounds per month, translating to 1–2 pounds weekly. This early phase often shows the most dramatic results because the medication reduces calorie intake significantly.
Weight loss typically plateaus or slows between months 3–6 as the body adapts to the medication and calorie deficit stabilizes. By month six, many patients report cumulative losses of 15–25 pounds, depending on starting weight, adherence, and lifestyle factors. The curve then tends to flatten unless dose escalation occurs or additional behavioral changes are implemented.
After six months, continued weight loss becomes more gradual, averaging 0.5–1.5 pounds per week for responders. This slower pace is normal and reflects the body's adaptive mechanisms, not treatment failure. Patients who maintain consistent dietary habits and physical activity typically sustain reductions through month twelve and beyond.
Why Monthly Weight Loss Varies Among Individuals
Genetic factors significantly influence how quickly someone loses weight on semaglutide. Variations in genes controlling the GLP-1 receptor (such as rs6923761) and the GIPR gene (rs1800437) affect how efficiently the medication engages appetite-suppression pathways. PlexusDx's Precision Peptide Genetic Test identifies these variants, helping predict responder status and optimal therapy selection.
Baseline metabolic rate, starting body weight, age, and sex all modulate monthly weight loss. Patients with higher baseline metabolic rates and greater initial obesity often experience faster early losses. Conversely, older adults or those with metabolic syndrome may see more gradual progress, which is still clinically meaningful.
Adherence to dose escalation schedules directly impacts results. Semaglutide begins at low doses to minimize side effects, then increases weekly or bi-weekly over several weeks. Patients who reach therapeutic doses faster tend to lose weight more consistently than those with slower titration or dose tolerance issues.
Clinical Trial Data on Semaglutide Weight Loss
The landmark STEP trials enrolled over 4,500 adults with obesity and tracked weight loss across 68 weeks of semaglutide therapy versus placebo. Participants on the 2.4 mg weekly dose lost an average of 35 pounds (15% of baseline body weight), while placebo recipients lost only 6 pounds. These results established semaglutide as one of the most effective weight-loss medications available.
Subgroup analysis revealed that patients with the greatest baseline weight loss momentum (first 12 weeks) often achieved the largest total reductions by trial end. Monthly weight loss of 3–4 pounds in weeks 1–12 predicted 25–30 pound cumulative loss by week 68. This early-response pattern helps clinicians identify who will benefit most from continued therapy.
Real-world data from clinical practices mirrors trial outcomes when patients maintain consistent dosing and lifestyle support. Average weight loss of 15–22% of body weight over one year is reproducible across diverse patient populations, though individual results range from 5% to 30% depending on genetic and behavioral variables.
Optimizing Monthly Weight Loss with Personalized Semaglutide Therapy
PlexusDx offers compounded semaglutide injections starting at $149 per month, with no flat per-compound pricing increases—patients can adjust doses as needed without price changes. Dose escalation is individualized based on response and tolerance, allowing clinicians to find the optimal therapeutic level for each patient.
The Precision Peptide Genetic Test identifies genetic predispositions affecting peptide-pathway function, including semaglutide response genes and metabolic variants like FTO (rs9939609) and MC4R (rs17782313). Knowing these variants helps clinicians tailor initial dose selection and anticipate which patients may need higher doses to achieve target weight loss.
Combining semaglutide with consistent dietary changes and 150+ minutes weekly of moderate activity maximizes monthly weight loss potential. Behavioral support, hydration, and adequate protein intake help preserve lean mass during weight loss. PlexusDx patients can pursue genetic testing after the first month to refine long-term treatment strategies and predict sustainability.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
How much weight should I expect to lose in my first month on semaglutide?
Most patients lose 4–8 pounds in the first month, though some experience faster initial losses if they begin at a higher therapeutic dose. Results depend on starting weight, dose level, and how strictly you adhere to dietary changes. Consistent monthly losses of 3–5 pounds are typical during the first three months.
Is 1–2 pounds per week realistic for semaglutide therapy?
Yes, clinical trials show weekly weight losses of 1–2 pounds are achievable during the first 12 weeks, especially as doses reach therapeutic levels. However, this rate usually slows after month four as metabolic adaptation occurs. Total weight loss of 15–22% of body weight over one year remains the evidence-based expectation.
Can I get semaglutide at PlexusDx and what does it cost?
PlexusDx provides compounded semaglutide injections from licensed 503A pharmacies at $149 per month, with no your dose may need to go up - your price won't goes up. Coverage extends to all 50 states, no insurance required, and HSA/FSA accounts are eligible. Precision Peptide Genetic Testing ($99) is available after your first month to personalize long-term outcomes.
What if my weight loss slows or plateaus after month three?
Plateaus are normal and reflect metabolic adaptation rather than treatment failure. Dose escalation, increased physical activity, dietary refinement, or adding behavioral interventions can restart momentum. Some patients benefit from the Precision Peptide Genetic Test to identify personalized response pathways and predict whether dose adjustment or medication switching may help.
How does the Precision Peptide Genetic Test improve weight loss outcomes?
PlexusDx's genetic test identifies variants in 14 peptide pathways, including GLP-1 receptor and GIPR genes that influence semaglutide effectiveness. Knowing your genetic profile helps predict whether you're a strong responder or may need dose adjustments, combination therapy, or alternative compounds like tirzepatide to maximize monthly weight loss and long-term sustainability.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
What Should I Eat on Wegovy for Best Results?
Understanding Ozempic: How Long Do Side Effects Last After Stopping?